… the MPTP-induced degenerative process in the nigrostriatal system will be assessed. Relevance to Diagnosis/Treatment of … expression of alpha-synuclein in the nigrostriatal system. If successful, this can be applied to other regions … delivery of microRNA’s 7 and 153 protect the nigrostriatal system from MPTP toxicity.   …

… in Parkinson’s disease (PD). Each of these signaling systems contributes to the brain inflammation and breakdown … Kv1.3. We further hypothesize that an imbalance in this system will lead over time to PD pathology.  Study Design:  … manipulation of the Kv1.3 and inflammasome signaling systems have on measures of PD progression to obtain a …

… will reduce alpha-synuclein accumulation in the nervous system and improve motor and non-motor symptoms, effectively … produce the human alpha-synuclein protein in their nervous system; these animals exhibit motor and non-motor symptoms … by measuring the levels of alpha-synuclein in the nervous system. Impact on Diagnosis/Treatment of Parkinson’s …

… medications worked on both the dopamine and serotonin systems. Parkinson’s medications for motor symptoms also work on the dopamine system, and taking antipsychotics blocked the effect of … for Parkinson’s psychosis, works only on the serotonin system. Clinical trials showed the drug eased psychosis …

… proteins associated with PD significantly impact the immune system, suggesting that PD might be an autoimmune disease. … initiated by inherited or age-related defects in the immune system whereby infections drive production of autoimmune T … pave the way for early treatments targeting the immune system, potentially preventing PD. The identification of a …

… biochemical assays for LRRK1. Project Description :  Multiple approaches will be taken to both produce active, …